vs
Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $164.7M, roughly 1.3× PTC THERAPEUTICS, INC.). UNIVERSAL TECHNICAL INSTITUTE INC runs the higher net margin — 5.8% vs -82.0%, a 87.8% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (9.6% vs -22.7%). UNIVERSAL TECHNICAL INSTITUTE INC produced more free cash flow last quarter ($-19.2M vs $-36.6M). Over the past eight quarters, UNIVERSAL TECHNICAL INSTITUTE INC's revenue compounded faster (9.5% CAGR vs -11.5%).
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
PTCT vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $164.7M | $220.8M |
| Net Profit | $-135.0M | $12.8M |
| Gross Margin | — | — |
| Operating Margin | -43.3% | 7.1% |
| Net Margin | -82.0% | 5.8% |
| Revenue YoY | -22.7% | 9.6% |
| Net Profit YoY | -104.8% | -42.1% |
| EPS (diluted) | $-1.63 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $164.7M | $220.8M | ||
| Q3 25 | $211.0M | $222.4M | ||
| Q2 25 | $178.9M | $204.3M | ||
| Q1 25 | $1.2B | $207.4M | ||
| Q4 24 | $213.2M | $201.4M | ||
| Q3 24 | $196.8M | $196.4M | ||
| Q2 24 | $186.7M | $177.5M | ||
| Q1 24 | $210.1M | $184.2M |
| Q4 25 | $-135.0M | $12.8M | ||
| Q3 25 | $15.9M | $18.8M | ||
| Q2 25 | $-64.8M | $10.7M | ||
| Q1 25 | $866.6M | $11.4M | ||
| Q4 24 | $-65.9M | $22.2M | ||
| Q3 24 | $-106.7M | $18.8M | ||
| Q2 24 | $-99.2M | $5.0M | ||
| Q1 24 | $-91.6M | $7.8M |
| Q4 25 | -43.3% | 7.1% | ||
| Q3 25 | 1.4% | 11.2% | ||
| Q2 25 | -19.5% | 6.9% | ||
| Q1 25 | 82.5% | 8.1% | ||
| Q4 24 | -76.2% | 13.6% | ||
| Q3 24 | -27.7% | 13.3% | ||
| Q2 24 | -21.5% | 4.2% | ||
| Q1 24 | -21.6% | 6.1% |
| Q4 25 | -82.0% | 5.8% | ||
| Q3 25 | 7.5% | 8.4% | ||
| Q2 25 | -36.3% | 5.2% | ||
| Q1 25 | 73.7% | 5.5% | ||
| Q4 24 | -30.9% | 11.0% | ||
| Q3 24 | -54.2% | 9.6% | ||
| Q2 24 | -53.1% | 2.8% | ||
| Q1 24 | -43.6% | 4.2% |
| Q4 25 | $-1.63 | $0.23 | ||
| Q3 25 | $0.20 | $0.33 | ||
| Q2 25 | $-0.83 | $0.19 | ||
| Q1 25 | $10.04 | $0.21 | ||
| Q4 24 | $-0.85 | $0.40 | ||
| Q3 24 | $-1.39 | $0.35 | ||
| Q2 24 | $-1.29 | $0.09 | ||
| Q1 24 | $-1.20 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $162.8M |
| Total DebtLower is stronger | — | $101.4M |
| Stockholders' EquityBook value | $-205.3M | $335.9M |
| Total Assets | $2.9B | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9B | $162.8M | ||
| Q3 25 | $1.7B | $169.1M | ||
| Q2 25 | $2.0B | $70.7M | ||
| Q1 25 | $2.0B | $96.0M | ||
| Q4 24 | $1.1B | $172.0M | ||
| Q3 24 | $1.0B | $161.9M | ||
| Q2 24 | $1.1B | $115.5M | ||
| Q1 24 | $884.8M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $-205.3M | $335.9M | ||
| Q3 25 | $-155.8M | $328.1M | ||
| Q2 25 | $-206.5M | $306.8M | ||
| Q1 25 | $-185.8M | $293.9M | ||
| Q4 24 | $-1.1B | $280.0M | ||
| Q3 24 | $-1.1B | $260.2M | ||
| Q2 24 | $-980.2M | $239.4M | ||
| Q1 24 | $-893.9M | $232.6M |
| Q4 25 | $2.9B | $834.0M | ||
| Q3 25 | $2.6B | $826.1M | ||
| Q2 25 | $2.6B | $740.8M | ||
| Q1 25 | $2.7B | $720.4M | ||
| Q4 24 | $1.7B | $753.8M | ||
| Q3 24 | $1.8B | $744.6M | ||
| Q2 24 | $1.9B | $706.0M | ||
| Q1 24 | $1.8B | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.3M | $3.1M |
| Free Cash FlowOCF − Capex | $-36.6M | $-19.2M |
| FCF MarginFCF / Revenue | -22.3% | -8.7% |
| Capex IntensityCapex / Revenue | 1.4% | 10.1% |
| Cash ConversionOCF / Net Profit | — | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | $702.3M | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.3M | $3.1M | ||
| Q3 25 | $-66.3M | $57.1M | ||
| Q2 25 | $-58.3M | $18.1M | ||
| Q1 25 | $870.1M | $-789.0K | ||
| Q4 24 | $-30.0M | $23.0M | ||
| Q3 24 | $-77.0M | $67.5M | ||
| Q2 24 | $-71.5M | $10.0M | ||
| Q1 24 | $70.8M | $-2.5M |
| Q4 25 | $-36.6M | $-19.2M | ||
| Q3 25 | $-69.7M | $40.6M | ||
| Q2 25 | $-59.6M | $6.8M | ||
| Q1 25 | $868.4M | $-11.7M | ||
| Q4 24 | $-33.8M | $19.6M | ||
| Q3 24 | $-77.5M | $60.0M | ||
| Q2 24 | $-78.8M | $3.0M | ||
| Q1 24 | $61.2M | $-8.4M |
| Q4 25 | -22.3% | -8.7% | ||
| Q3 25 | -33.1% | 18.3% | ||
| Q2 25 | -33.3% | 3.4% | ||
| Q1 25 | 73.8% | -5.7% | ||
| Q4 24 | -15.8% | 9.7% | ||
| Q3 24 | -39.4% | 30.6% | ||
| Q2 24 | -42.2% | 1.7% | ||
| Q1 24 | 29.1% | -4.6% |
| Q4 25 | 1.4% | 10.1% | ||
| Q3 25 | 1.6% | 7.4% | ||
| Q2 25 | 0.7% | 5.5% | ||
| Q1 25 | 0.1% | 5.3% | ||
| Q4 24 | 1.8% | 1.7% | ||
| Q3 24 | 0.3% | 3.8% | ||
| Q2 24 | 4.0% | 4.0% | ||
| Q1 24 | 4.6% | 3.2% |
| Q4 25 | — | 0.24× | ||
| Q3 25 | -4.17× | 3.04× | ||
| Q2 25 | — | 1.69× | ||
| Q1 25 | 1.00× | -0.07× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 3.58× | ||
| Q2 24 | — | 2.01× | ||
| Q1 24 | — | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PTCT
Segment breakdown not available.
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
